Titan pharmaceuticals steroids

We are a pharmaceutical company developing proprietary therapeutics for the treatment of serious medical disorders. Our product development programs utilize our proprietary long-term drug delivery platform, ProNeura(TM), and focus primarily on innovative treatments for select chronic diseases for which steady state delivery of a drug provides an efficacy and/or safety benefit. Probuphine®, our first product candidate based on the ProNeura platform, was approved by the United States Food and Drug Administration, or FDA, on May 26, 2016 for the maintenance treatment of opioid dependence in patients who are stable on low to moderate doses of daily sublingual buprenorphine treatment. We have licensed development and commercialization rights of Probuphine for the . and Canadian markets to Braeburn Pharmaceuticals, Inc.  ... More ...  

On February 21, 2014 Ariad Pharmaceuticals announced the appointment of Sarissa Capital's Alexander J. Denner, . to a two-year term on the company's Board of Directors. Previously, Denner served as a senior managing director at Carl Icahn's Icahn Capital and is currently Ariad's second-largest shareholder. On January 10, 2016, Ariad announced that Denner had become the chairman of the board, replacing Harvey Berger. [9] Shortly thereafter, the company announced the termination of its shareholder's rights plan (the "poison pill.") [10]

Titan pharmaceuticals steroids

titan pharmaceuticals steroids


titan pharmaceuticals steroidstitan pharmaceuticals steroidstitan pharmaceuticals steroidstitan pharmaceuticals steroidstitan pharmaceuticals steroids